Novo Nordisk Bets on Oral Wegovy to Expand Weight-Loss Market Reach

In a strategic pivot aimed at capturing a broader patient base, Novo Nordisk is aggressively promoting a new oral version of its weight-loss drug, Wegovy. The shift, moving beyond reliance on injectable treatments, was detailed by CEO Mike Doustdar at the recent J.P. Morgan Healthcare Conference. The core question for investors is whether this pill can successfully unlock a significantly larger segment of the mass market.

Since assuming the CEO role in August 2025, Mike Doustdar has been reshaping the company’s narrative. The central pillar of this new direction is the U.S. launch of an oral Wegovy formulation, explicitly designed to tap into a previously underserved demographic. A key Read more...